SLAM BioTherapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SLAM BioTherapeutics, Inc. - overview
Established
2022
Location
Thousand Oaks, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2022 by co-founders Dr. Steven Rosen, Rick Heinick, and Prof. Idit Shachar, SLAM BioTherapeutics, Inc. operates as a preclinical-stage biotech company that researches antibody therapeutics for cancer and autoimmune diseases.
In January 2024, SLAM BioTherapeutics, Inc. raised USD 8 million in seed funding from Schwartz Capital Group. The company provides a collection of antibodies that target a unique cell surface receptor found in the tumor microenvironment.
Current Investors
Schwartz Capital Group
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.slambio.com/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.